Abivax (NASDAQ:ABVX) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Abivax (NASDAQ:ABVX) from a "hold" to a "sell" in a report released Sunday.
• Despite that downgrade, the consensus among analysts remains a Moderate Buy with a consensus target price of $137.15 and several firms issuing target prices up to $150.
• Abivax has a $9.08 billion market cap but reported a quarterly loss (EPS -$1.20) on just $0.52M revenue and is forecast to post -3.84 EPS for the year, while institutional investors own about 47.91% of the stock.

Abivax (NASDAQ:ABVX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday.

A number of other equities research analysts have also recently commented on ABVX. Wedbush initiated coverage on shares of Abivax in a research note on Tuesday, February 24th. They set an "outperform" rating and a $110.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Abivax in a research note on Monday, April 20th. Oppenheimer set a $131.00 target price on shares of Abivax in a research note on Thursday, January 8th. Morgan Stanley raised their target price on shares of Abivax from $101.00 to $145.00 and gave the stock an "overweight" rating in a research note on Friday, January 9th. Finally, BTIG Research restated a "buy" rating and set a $150.00 target price on shares of Abivax in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.15.

Abivax Price Performance

Shares of Abivax stock opened at $114.56 on Friday. Abivax has a 1 year low of $5.59 and a 1 year high of $148.83. The firm has a market cap of $9.08 billion, a price-to-earnings ratio of -21.33 and a beta of 1.68. The company has a 50-day moving average of $118.27 and a 200 day moving average of $115.89.

Abivax (NASDAQ:ABVX - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The business had revenue of $0.52 million for the quarter. On average, equities analysts anticipate that Abivax will post -3.84 EPS for the current year.

Institutional Investors Weigh In On Abivax

Several institutional investors and hedge funds have recently modified their holdings of ABVX. UBS Group AG raised its position in shares of Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company's stock valued at $378,761,000 after buying an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of Abivax during the third quarter valued at approximately $263,698,000. Morgan Stanley raised its position in shares of Abivax by 114.3% during the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company's stock valued at $425,062,000 after buying an additional 1,681,277 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new stake in shares of Abivax during the third quarter valued at approximately $132,800,000. Finally, TCG Crossover Management LLC raised its position in shares of Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company's stock valued at $603,774,000 after buying an additional 1,055,000 shares during the last quarter. Institutional investors own 47.91% of the company's stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.